Janssen Vaccines & Prevention B.V.
Leiden, Zuid-Holland, Netherlands
Purpose
to perform pre-clinical and clinical safety and immunogenicity studies to determine if inactivated poliomyelitis vaccine (IPV) derived from PER.C6 produced virus has the biological properties that would justify commercial production
Division
Global Development
Date
October 2013
Region Served
GLOBAL
Committed amount
$30,392,943
Grant topic
Polio
Duration (months)
116
Grantee location
Leiden, Zuid-Holland, Netherlands
Related work
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.